ALB and neoplasm: For example, Fronik et al. developed a triple-action platinum(IV) prodrug, designed for tumour targeting via maleimide-mediated albumin binding, also for release of the immunomodulatory ligand 1-methyl-d-tryptophan (1-MDT) [155].